Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Accumulated Expenses (2022 - 2025)

Mereo BioPharma (MREO) has disclosed Accumulated Expenses for 4 consecutive years, with $4.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses rose 16.69% to $4.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.1 million, a 16.69% increase, with the full-year FY2024 number at $4.1 million, down 25.54% from a year prior.
  • Accumulated Expenses was $4.1 million for Q3 2025 at Mereo BioPharma, down from $5.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $5.5 million in Q4 2023 to a low of $2.5 million in Q1 2024.
  • A 4-year average of $4.1 million and a median of $4.1 million in 2024 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: dropped 25.54% in 2024, then soared 35.47% in 2025.
  • Mereo BioPharma's Accumulated Expenses stood at $5.4 million in 2022, then grew by 0.57% to $5.5 million in 2023, then fell by 25.54% to $4.1 million in 2024, then rose by 1.15% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Accumulated Expenses are $4.1 million (Q3 2025), $5.0 million (Q2 2025), and $2.9 million (Q1 2025).